retatrutide georgia (LY3437943) | GCGR/GIPR/GLP-1R Agonist Retatrutide 10mg — Triple Agonist

Video visit: Meet a Southwestern Medical Center doctor to confirm if treatment is appropriate

Lilly became the first healthcare company worth a trillion dollars in late 2025, built substantially on tirzepatide, and in the first quarter of 2026 alone it booked $19.8 billion in revenue

Again, a medication prescribed for diabetes management is more likely to be covered

Source: ClinicalTrials.gov NCT05929066 The 68-week results showed continued weight loss beyond the Phase 2 endpoint, with participants on 12mg losing an average of 28.7% of their body weight

Its no longer just a line item in your budget

Combining Retatrutide with other GLP-1 or GIP agonists like Semaglutide or Tirzepatide is not recommended due to overlapping mechanisms and increased side effect risk